SGSonsoles Garcia-Valdecasas Gayo

Sonsoles Garcia-Valdecasas Gayo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sonsoles Garcia-Valdecasas Gayo has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Ignacio Arribas

    Departamento de Análisis Clínicos , Hospital Universitario Ramón y Cajal University , Madrid , España

    3 shared publications
  • Daniel Gonzalez-Gay

    Departamento de Análisis Clínicos , BR Salud, Hospital Infanta Sofía , Madrid , España

    2 shared publications
  • Eva Marquez-Lietor

    Departamento de Análisis Clínicos , BR Salud, Hospital Infanta Sofía , Madrid , España

    2 shared publications
  • Fernando Cava-Valenciano

    Departamento de Análisis Clínicos , BR Salud, Hospital Infanta Sofía , Madrid , España

    2 shared publications
  • Maria Jesus Ruiz-Alvarez

    Departamento de Análisis Clínicos , BR Salud, Hospital Infanta Sofía , Madrid , España

    2 shared publications
  • Maria del Carmen Plata

    Departamento de Análisis Clínicos , BR Salud, Hospital Infanta Sofía , Madrid , España

    2 shared publications

Latest Publications

  • Open Access

    El CYFRA 21-1 en pacientes con sospecha de cáncer: evaluación de un punto de corte óptimo para evaluar la eficacia diagnóstica y el valor pronóstico

    by Sonsoles Garcia-Valdecasas Gayo, Maria Jesus Ruiz-Alvarez, Daniel Gonzalez-Gay, Raquel Ramos-Corral, Eva Marquez-Lietor, Nazaret Del Amo, Maria del Carmen Plata, Raquel Guillén-Santos, Ignacio Arribas, Fernando Cava-Valenciano

    Resumen: Objetivos: El punto de corte utilizado del CYFRA 21-1 como marcador tumoral influye considerablemente en su utilidad diagnóstica y pronóstica. El objetivo de este estudio es establecer un punto de corte óptimo de CYFRA 21-1 que tenga validez diagnóstica, determinado con la tecnología Lumipulse® en pacientes con sospecha de cáncer. El objetivo secundario de este estudio es determinar si los niveles de CYFRA 21-1 tienen valor pronóstico. Métodos: Se llevó a cabo un estudio retrospectivo en una muestra compuesta por 284 pacientes con sospecha de enfermedad maligna procedentes de seis hospitales de Madrid. El punto de corte se obtuvo mediante la curva ROC y el test de Youden. La validez diagnóstica se evaluó de acuerdo con la sensibilidad, especificidad, valores predictivos y ratios de probabilidad. El valor pronóstico de CYFRA 21-1 se determinó por medio de la regresión logística múltiple. Se confirmaron un total de 32 casos de cáncer. Resultados: El punto de corte más óptimo fue 3,15 ng/mL. Este punto de corte mostró mejor especifidad, de 93,63% (89,66–96,16; IC 95%), Valor Predictivo Positivo (44,54–75,38; IC 95%) y Razón de Probabilidad Positiva 12,65 (7,64–20,95; IC 95%) que el punto de corte recomendado por Fujirebio® (1,8 ng/mL); con una especifidad de 73,71% (67,72–78,95; IC 95%), Valor Predictivo Positivo: 29,79% (21,02–40,23; IC 95%) y una Razón de Probabilidad Positiva de 3,43 (2,71–4,35; IC 95%), mejorando la precisión diagnóstica actual. En el análisis multivariante, se confirmó que los niveles elevados de CYFRA 21-1 (>3,15 ng/mL) son un factor pronóstico desfavorable. Conclusiones: El mejor punto de corte obtenido para CYFRA 21-1 fue de 3,15 ng/mL en pacientes con sospecha de cáncer. Este nuevo punto de corte reduce la tasa de falsos positivos y mejora la eficacia diagnóstica de CYFRA 21-1 como marcador tumoral, así como su asociación con la mortalidad.


  • Open Access

    CYFRA 21-1 in patients with suspected cancer: evaluation of an optimal cutoff to assess the diagnostic efficacy and prognostic value

    by Sonsoles Garcia-Valdecasas Gayo, Maria Jesus Ruiz-Alvarez, Daniel Gonzalez-Gay, Raquel Ramos-Corral, Eva Marquez-Lietor, Nazaret Del Amo, Maria del Carmen Plata, Raquel Guillén-Santos, Ignacio Arribas, Fernando Cava-Valenciano

    Objectives: Chosen cutoff for cytokeratin 19 fragment antigen (CYFRA 21-1) as a tumor biomarker considerably influences its diagnostic and prognostic usefulness. The aim of the present study is to determine an optimal cutoff value for diagnostic validity of CYFRA 21-1 by Lumipulse ® technology in patients with suspected cancer and also to determine if CYFRA 21-1 levels provide prognostic value. Methods: A consecutive 284 patients suggestive of malignant disease from six hospitals of Madrid were enrolled in a retrospective design. Optimal CYFRA 21-1 cutoff value was obtained by receiver operating characteristic curve and Youden test. The diagnostic validity was evaluated according to sensitivity, specificity, predictive values and likelihood ratios. The prognostic value of CYFRA 21-1 was checked using multiple logistic regression. Thirty-two diagnostic cancers were confirmed. Results: The most optimal cutoff was 3.15 ng/mL. This cutoff showed a better specificity 93.63% (95% confidence interval [CI], 89.66–96.16), positive predictive value 60.98% (95% CI, 44.54–75.38) and positive likelihood ratio 12.65 (95% CI, 7.64–20.95) than the cutoff recommended by Fujirebio® (1.8 ng/mL) (specificity: 73.71% [95% CI, 67.72–78.95], positive predictive value: 29.79% [95% CI, 21.02–40.23] and positive likelihood ratio 3.43 [95% CI, 2.71–4.35]), improving the current diagnostic accuracy. In multivariate analysis, elevated levels of CYFRA 21-1 (>3.15 ng/mL) was confirmed as an unfavorable prognostic factor. Conclusions: The best cutoff for CYFRA 21-1 obtained was 3.15 ng/mL in patients with suspected cancer. This new cutoff decreases the false positive rate and improves the diagnostic efficacy of CYFRA 21-1 as a tumor marker as well as its association with death events.


  • Diagnostic and prognostic value of heart-type fatty acid-binding protein in the early hours of acute myocardial infarction

    by Sonsoles Garcia-Valdecasas, Maria J. Ruiz-Alvarez, Jaime Garcia De Tena, Raul De Pablo, Isabel Huerta, Marta Barrionuevo, Carmen Coca, Ignacio Arribas

    Background Heart-type fatty acid-binding protein (H-FABP) is a cytosolic protein that is released into the bloodstream when the myocardium is injured. The aim was to determine the diagnostic and prognostic value of H-FABP in patients with suspected acute myocardial infarction (AMI) within the fi rst 3-6 hours after the onset of chest pain. Methods and results A consecutive series of 165 patients with chest pain lasting less than 6 hours were enrolled in a forward observational design in the emergency department. The diagnostic validity of H-FABP was evaluated according to sensitivity, specifi city, and predictive values, likelihood ratios, ROC curves, and multivariate logistic regression analyses. The prognostic value of H-FABP at 6 months was checked using survival curves and the multivariate Cox proportional hazards model. The sensitivity of H-FABP was 81% (95% CI: 69.2-92.9). Its area under the ROC curve: 0.729 (95% CI: 0.63-0.83) and negative likelihood ratio (0.38; 95% CI: 0.22-0.65) were signifi cantly better than both troponin (cTnI) and CK-MB, whereas its specifi city, 53% (95% CI: 41.1-64.8), was lower than that of the other markers. Increased H-FABP added diagnostic information as it demonstrated independent association with AMI by logistic regression analysis. Increased H-FABP and cTnI were both strong and independent predictors of outcome in the 6-month follow-up (hazard ratio: 2.18; 95% CI: 1.07-4.42; and 2.34; 95% CI: 0.98-5.59, respectively). Conclusions H-FABP is, within 6 hours and also within 3 hours, more sensitive than the other markers in the early diagnosis of AMI and it is an independent prediction factor of events within 6 months.